We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.

You are here

Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia: The NODE-301 Trial

IRB Protocol #: 1801018891

Overview: The purpose of this study is to collect data that may determine whether the study drug, an investigational drug known as etripamil nasal spray, is able to effectively stop an episode of PSVT when taken by a patient to self-treat their PSVT episode. Paroxysmal Supraventricular Tachycardia (PSVT) is an arrhythmia (or heart rhythm disorder) that results in sudden episodes of rapid heart rate, usually at a rate greater than 100 beats per minute. A normal heart rate is about 60 beats per minute. 

This trial is funded by Milestone Pharmaceuticals

To be eligible, patients must:

•   Be older than 18

•   Have been diagnosed with PSVT 

Patients cannot participate if:

•   Diagnosed with hypotension

•   Allergic to verapamil

•   Currently being treated with amiodarone

•   Have a history of severe ventricular arrhythmia

•   Have been diagnosed with congestive heart failure

•   Have suffered a stroke in the past 6 months


Dr. James Ip
Principle Investigator
Email: jei9008@med.cornell.edu
Phone: (212) 746-2158

Rosa Chu
Research Coordinator
Email: roc2025@med.cornell.edu
Phone: (212) 746-4857

Make an Appointment

(646) 962-5558

Weill Cornell Medicine
Division of Cardiology

520 East 70th Street
Starr 443
New York, NY 10021

1305 York Avenue, 8th Floor
New York, NY 10021